{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:40:19Z","timestamp":1792806019555,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jhepr.2024.101164","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T13:54:08Z","timestamp":1719842048000},"page":"101164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0910-153X","authenticated-orcid":false,"given":"Ayesha A.","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase J.","family":"Wehrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ferreira-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-8243","authenticated-orcid":false,"given":"Chunbao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-7148","authenticated-orcid":false,"given":"Neda","family":"Dadgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3310-9646","authenticated-orcid":false,"given":"Jorge","family":"Arpi-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Phoon","family":"Phong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-6655","authenticated-orcid":false,"given":"Jaekeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David CH.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-7691","authenticated-orcid":false,"given":"Nic","family":"Leipzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Wee","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-537X","authenticated-orcid":false,"given":"Jos","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Aucejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-9847","authenticated-orcid":false,"given":"Andrea","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101164_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2021.04.008","article-title":"Examining the gut-liver axis in liver cancer using organoid models","volume":"510","author":"Shek","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2024.101164_bib2","first-page":"15","article-title":"Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2024.101164_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.32604\/or.2023.029718","article-title":"Mini-organs with big impact: organoids in liver cancer studies","volume":"31","author":"Khawar","year":"2023","journal-title":"Oncol Res"},{"key":"10.1016\/j.jhepr.2024.101164_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fonc.2022.1105454","article-title":"Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening","volume":"12","author":"Xie","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2024.101164_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054529","article-title":"Liver organoids as an in\u00a0vitro model to study primary liver cancer","volume":"24","author":"De Siervi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2024.101164_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1175503","article-title":"3D cancer models: one step closer to in\u00a0vitro human studies","volume":"14","author":"Manduca","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2024.101164_bib7","first-page":"1783","article-title":"Organoids: approaches and utility in cancer research","volume":"136","author":"Zhou","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jhepr.2024.101164_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231154090","article-title":"Updates on organoid model for the study of liver cancer","volume":"22","author":"El-Khobar","year":"2023","journal-title":"Technology Cancer Res Treat"},{"key":"10.1016\/j.jhepr.2024.101164_bib9","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2024.101164_bib10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2023.02.045","article-title":"Refining classification of cholangiocarcinoma subtypes via proteogenomic integration reveals new therapeutic prospects","volume":"164","author":"Cho","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2024.101164_bib11","first-page":"164","article-title":"Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening","volume":"18","author":"Dong","year":"2022","journal-title":"Bioact Mater"},{"key":"10.1016\/j.jhepr.2024.101164_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbrc.2021.01.085","article-title":"METTL3\/IGF2BP1\/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC","volume":"546","author":"Fan","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhepr.2024.101164_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3358","article-title":"Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology","volume":"15","author":"Ji","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2024.101164_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/cells11223613","article-title":"Label-free imaging analysis of patient-derived cholangiocarcinoma organoids after sorafenib treatment","volume":"11","author":"Koch","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2024.101164_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-022-00445-z","article-title":"LPA receptor 1 (LPAR1) is a novel interaction partner of Filamin A that promotes Filamin A phosphorylation, MRTF-A transcriptional activity and oncogene-induced senescence","volume":"11","author":"Konopa","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jhepr.2024.101164_bib16","article-title":"Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2024.101164_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1172\/jci.insight.121490","article-title":"Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity","volume":"4","author":"Li","year":"2019","journal-title":"Jci Insight"},{"key":"10.1016\/j.jhepr.2024.101164_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s10020-022-00498-1","article-title":"Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification","volume":"28","author":"Lieshout","year":"2022","journal-title":"Mol Med"},{"key":"10.1016\/j.jhepr.2024.101164_bib19","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/gutjnl-2020-322196","article-title":"High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells","volume":"70","author":"Liu","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101164_bib20","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.stemcr.2022.06.003","article-title":"Human liver organoids for disease modeling of fibrolamellar carcinoma","volume":"17","author":"Narayan","year":"2022","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jhepr.2024.101164_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid models of human liver cancers derived from tumor needle biopsies","volume":"24","author":"Nuciforo","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2024.101164_bib22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","article-title":"Establishment of patient-derived organoids and drug screening for biliary tract carcinoma","volume":"27","author":"Saito","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2024.101164_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092668","article-title":"A\u00a0human organoid model of aggressive hepatoblastoma for disease modeling and drug testing","volume":"12","author":"Saltsman","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101164_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cells11223657","article-title":"Scalable production of size-controlled cholangiocyte and cholangiocarcinoma organoids within liver extracellular matrix-containing microcapsules","volume":"11","author":"Van Tienderen","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2024.101164_bib25","article-title":"Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors","volume":"9","author":"Wang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jhepr.2024.101164_bib26","first-page":"13","article-title":"Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2024.101164_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-021-02219-w","article-title":"Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids","volume":"21","author":"Wang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jhepr.2024.101164_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1476","article-title":"As sociation of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma","volume":"6","author":"Xin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2024.101164_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2022.215898","article-title":"Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity","volume":"548","author":"Xu","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2024.101164_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/liv.14692","article-title":"The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer","volume":"41","author":"Zhang","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2024.101164_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216405","article-title":"Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy","volume":"576","author":"Zhang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2024.101164_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/advs.202003897","article-title":"Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids","volume":"8","author":"Zhao","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.jhepr.2024.101164_bib33","article-title":"Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients","volume":"10","author":"Zou","year":"2023","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.jhepr.2024.101164_bib34","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/hep.32000","article-title":"YAP\/TAZ suppress drug penetration into hepatocellular carcinoma through stromal activation","volume":"74","author":"Cho","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101164_bib35","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1002\/hep4.2055","article-title":"\u03b2-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma","volume":"6","author":"Gulati","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2024.101164_bib36","article-title":"3d organoid modelling of hepatoblast-like and mesenchymal-like hepatocellular carcinoma cell lines","volume":"7","author":"Oz","year":"2021","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jhepr.2024.101164_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030931","article-title":"Niclosamide revitalizes sorafenib through insulin-like growth factor 1 receptor (IGF-1R)\/Stemness and metabolic changes in hepatocellular carcinoma","volume":"15","author":"Peng","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101164_bib38","doi-asserted-by":"crossref","first-page":"776-+","DOI":"10.1016\/j.stem.2022.04.011","article-title":"Human branching cholangiocyte organoids functional bile duct formation","volume":"29","author":"Roos","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2024.101164_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/15476278.2017.1322243","article-title":"Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancyrelated hallmarks","volume":"13","author":"Wang","year":"2017","journal-title":"Organogenesis"},{"key":"10.1016\/j.jhepr.2024.101164_bib40","first-page":"9","article-title":"BNIP3 upregulation characterizes cancer cell subpopulation with increased fitness and proliferation","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2024.101164_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.31083\/j.fbl2701018","article-title":"Screening a redox library identifies the anti-tumor drug Hinokitiol for treating intrahepatic cholangiocarcinoma","volume":"27","author":"Bai","year":"2022","journal-title":"Front Biosci"},{"key":"10.1016\/j.jhepr.2024.101164_bib42","article-title":"Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation","volume":"9","author":"Fujiwara","year":"2019","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhepr.2024.101164_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41467-020-15846-0","article-title":"LGR5 marks targetable tumor-initiating cells in mouse liver cancer","volume":"11","author":"Cao","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2024.101164_bib44","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/TP.0000000000002647","article-title":"Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients","volume":"103","author":"Chen","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2024.101164_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105679","article-title":"Steroidal saponins from Trillium tschonoskii rhizome repress cancer stemness and proliferation of intrahepatic cholangiocarcinoma","volume":"121","author":"Pang","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jhepr.2024.101164_bib46","doi-asserted-by":"crossref","first-page":"1015-+","DOI":"10.1038\/s41556-019-0359-5","article-title":"Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes","volume":"21","author":"Sun","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jhepr.2024.101164_bib47","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1038\/s41467-023-37951-6","article-title":"Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss","volume":"14","author":"R\u00fcland","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2024.101164_bib48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.stem.2023.04.011","article-title":"Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation","volume":"30","author":"Vandana","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2024.101164_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091410","article-title":"The potential clinical use of stem\/progenitor cells and organoids in liver diseases","volume":"11","author":"Nikokiraki","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2024.101164_bib50","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.jhepr.2024.101164_bib51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12079-021-00643-1","article-title":"Matrigel: history\/background, uses, and future applications","volume":"16","author":"Passaniti","year":"2022","journal-title":"J\u00a0Cell Commun Signal"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592400168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592400168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T20:18:47Z","timestamp":1745266727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592400168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S258955592400168X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101164","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101164"}}